These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 24105106)
1. Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Wang M; Zhang Q; Huang M; Zong S; Hua W; Zhou W Drug Res (Stuttg); 2014 May; 64(5):263-8. PubMed ID: 24105106 [TBL] [Abstract][Full Text] [Related]
2. Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. Ge J; Ding LK; Yang J; Jia YY; Lu CT; Ding Y; Song Y; Song W; Wen AD Int J Clin Pharmacol Ther; 2015 Mar; 53(3):272-6. PubMed ID: 25546165 [TBL] [Abstract][Full Text] [Related]
3. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study. Izquierdo I; Borja J; Rovira S; Pelagio P; Torres F; Cebrecos J; García-Rafanell J Arzneimittelforschung; 2010; 60(1):36-41. PubMed ID: 20184225 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Ramis J; Mis R; Forn J; Torrent J; Gorina E; Jané F Eur J Drug Metab Pharmacokinet; 1991; 16(4):269-73. PubMed ID: 1823870 [TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. Quetglas EG; Campanero MA; Sádaba B; Escolar M; Azanza JR Arzneimittelforschung; 2008; 58(6):283-7. PubMed ID: 18677970 [TBL] [Abstract][Full Text] [Related]
6. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Yun HY; Baek IH; Kwon KI; Yoon YR Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1471-9. PubMed ID: 22098139 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of triflusal and its main metabolite in rats and dogs. Ramis J; Mis R; Forn J Eur J Drug Metab Pharmacokinet; 1991; 16(4):261-8. PubMed ID: 1823869 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. Ferrari E; Reboldi G; Marenco P; D'Angelo L; Crema F; Ambrosoli L; Poli A; Girardello R; Lowenthal DT Am J Ther; 1996 Sep; 3(9):630-636. PubMed ID: 11862303 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747 [TBL] [Abstract][Full Text] [Related]
10. Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. Valle M; Barbanoj MJ; Donner A; Izquierdo I; Herranz U; Klein N; Eichler HG; Müller M; Brunner M Eur J Clin Pharmacol; 2005 Apr; 61(2):103-11. PubMed ID: 15711832 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of triflusal after single and repeated doses in man. Ramis J; Torrent J; Mis R; Conte L; Barbanoj MJ; Jané J; Forn J Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):344-9. PubMed ID: 2272716 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. Cho HY; Jeong TJ; Lee YB J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Dec; 798(2):257-64. PubMed ID: 14643505 [TBL] [Abstract][Full Text] [Related]
13. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364 [TBL] [Abstract][Full Text] [Related]
14. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions. Huang NY; Ding L; Wang J; Zhang QY; Liu X; Lin HD; Hua WY Drug Res (Stuttg); 2013 Aug; 63(8):388-95. PubMed ID: 23580109 [TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects. He J; Cao G; Yu J; Wang J; Cheng N; Wu J; Zhang J; Wu X; Zhang B; Lu J; Chen S Clin Drug Investig; 2021 Jan; 41(1):89-97. PubMed ID: 33355910 [TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study. Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tolerability of minodronic acid tablets in healthy Chinese subjects and food and age effects on the pharmacokinetics. Zhou Y; He X; Li H; Ni Y; Xu M; Sattar H; Chen H; Li W Clin Ther; 2015 Apr; 37(4):869-76. PubMed ID: 25748293 [TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study. Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]